Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a diabetes pill protect your heart before failure starts?

NCT ID NCT06055452

First seen Mar 06, 2026 · Last updated May 23, 2026 · Updated 17 times

Summary

This study tests a drug called engagliflozin (an SGLT2 inhibitor) in 120 people with high blood pressure who show early signs of heart strain but do not have diabetes or full heart failure. Participants will take either the drug or a placebo daily for 6 months. The goal is to see if the drug improves heart structure and function, potentially delaying or preventing heart failure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen

    RECRUITING

    Shenzhen, Guangdong, 518038, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100037, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.